Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellen Solomon

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Blood|August 18, 2005
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemiaRosemary E Gale, Robert Hills, Arnold R Pizzey, et al.
The Journal of Biological Chemistry|December 10, 2003
HLS5, a novel RBCC (ring finger, B box, coiled-coil) family member isolated from a hemopoietic lineage switch, is a candidate tumor suppressorJean-Philippe Lalonde, Raelene Lim, Evan Ingley, et al.
Cancer Cell|December 17, 2011
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistanceRinske Drost, Peter Bouwman, Sven Rottenberg, et al.
International Journal of Cancer|June 22, 2007
Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibilityJulian Barwell, Laurent Pangon, Anne Georgiou, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Neighbor of Brca1 gene (Nbr1) functions as a negative regulator of postnatal osteoblastic bone formation and p38 MAPK activityCaroline A Whitehouse, Sarah Waters, Katie Marchbank, et al.
Transgenic Research|November 20, 2002
Expression of a truncated Brca1 protein delays lactational mammary development in transgenic miceMelissa A Brown, Hans Nicolai, Kathy Howe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapyDavid Grimwade, Jelena V Jovanovic, Robert K Hills, et al.
Blood|November 4, 2009
Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemiaAshley N Mays, Neil Osheroff, Yuanyuan Xiao, et al.
The New England Journal of Medicine|January 21, 2016
Assessment of Minimal Residual Disease in Standard-Risk AMLAdam Ivey, Robert K Hills, Michael A Simpson, et al.
Blood|February 15, 2007
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemiaJelena V Jovanovic, Joannah Score, Katherine Waghorn, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Blood|August 18, 2005
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemiaRosemary E Gale, Robert Hills, Arnold R Pizzey, et al.
The Journal of Biological Chemistry|December 10, 2003
HLS5, a novel RBCC (ring finger, B box, coiled-coil) family member isolated from a hemopoietic lineage switch, is a candidate tumor suppressorJean-Philippe Lalonde, Raelene Lim, Evan Ingley, et al.
Cancer Cell|December 17, 2011
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistanceRinske Drost, Peter Bouwman, Sven Rottenberg, et al.
International Journal of Cancer|June 22, 2007
Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibilityJulian Barwell, Laurent Pangon, Anne Georgiou, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Neighbor of Brca1 gene (Nbr1) functions as a negative regulator of postnatal osteoblastic bone formation and p38 MAPK activityCaroline A Whitehouse, Sarah Waters, Katie Marchbank, et al.
Transgenic Research|November 20, 2002
Expression of a truncated Brca1 protein delays lactational mammary development in transgenic miceMelissa A Brown, Hans Nicolai, Kathy Howe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapyDavid Grimwade, Jelena V Jovanovic, Robert K Hills, et al.
Blood|November 4, 2009
Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemiaAshley N Mays, Neil Osheroff, Yuanyuan Xiao, et al.
The New England Journal of Medicine|January 21, 2016
Assessment of Minimal Residual Disease in Standard-Risk AMLAdam Ivey, Robert K Hills, Michael A Simpson, et al.
Blood|February 15, 2007
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemiaJelena V Jovanovic, Joannah Score, Katherine Waghorn, et al.
Pageof 5